临床肝胆病杂志2017，Vol.33Issue(1)：61-66,6.DOI:10.3969/j.issn.1001-5256.2017.01.013
江苏苏启东市 HBV 感染相关疾病的医疗费用及其影响因素分析
Medical expenditure of hepatitis B virus infection and its impact factors analysis in Qidong,Jiangsu Province
摘要
Abstract
riance was used for comparison between multiple groups,and the SNK -q test was used for comparison within each group.Multiple linear re-gression analysis (stepwise regression)was used to investigate the influencing factors for medical costs per case.Results The medical costs per case of patients with HBV related primary liver cancer,patients with HBV related cirrhosis,and CHB patients from 2010 to 2012 were 30183 RMB,22066 RMB,and 15703 RMB,respectively,and the inpatient costs were 29058 RMB,21383 RMB,and 15394 RMB,re-spectively,which accounted for 96.3%,96.9%,and 98.0% of the medical costs per case.Drug costs of these three groups accounted for 55.0%,73.4%,and 78.2% of the medical costs per case,respectively.The number of times of hospitalization (F =89.1,67.7,and 11.5,all P <0.001),treatment regimen (F =21.8,t =-2.1,and t =-3.7,P <0.001,P =0.039,and P <0.001),and type of medical insurance (t =3.1,2.6,and 2.7,P =0.002,0.011,and 0.012)were influencing factors for medical costs per case,while clini-cal stage was an influencing factor for medical costs per case only in CHB patients (a multivariate analysis for patients mild,moderate,and severe CHB:β=1.238,F =5.9,P =0.021).The medical costs per case for patients with acute hepatitis B were 5950 RMB,and the an-nual medical costs for HBsAg asymptomatic carriers and patients with occult HBV infection ranged from 770 RMB to 1540 RMB.Conclusion The medical costs of HBV related is increasing as the illness progresses.Our results will provide baseline information for the following eco-nomic evaluation of vaccination or screening interrention.关键词
肝炎病毒,乙型/医疗费用/经济负担Key words
hepatitis B virus/medical expenditure/economic burden分类
医药卫生引用本文复制引用
王宇婷,石菊芳,黄慧瑶,秦海松,姚红玉,陈松,郁冬梅,代敏,陈陶阳,曲春枫..江苏苏启东市 HBV 感染相关疾病的医疗费用及其影响因素分析[J].临床肝胆病杂志,2017,33(1):61-66,6.基金项目
“十二五”传染病国家科技重大专项（2012ZX10002008－001，003）；江苏省科技支撑计划 （）
